The mechanistic target of rapamycin (mTOR) pathway coordinates the metabolic activity of eukaryotic cells through environmental signals, including nutrients, energy, growth factors, and oxygen. In the nervous system, the mTOR pathway regulates fundamental biological processes associated with neural development and neurodegeneration. Intriguingly, genes that constitute the mTOR pathway have been found to be germline and somatic mutation from patients with various epileptic disorders. Hyperactivation of the mTOR pathway due to said mutations has garnered increasing attention as culprits of these conditions : somatic mutations, in particular, in epileptic foci have recently been identified as a major genetic cause of intractable focal epilepsy, such as focal cortical dysplasia. Meanwhile, epilepsy models with aberrant activation of the mTOR pathway have helped elucidate the role of the mTOR pathway in epileptogenesis, and evidence from epilepsy models of human mutations recapitulating the features of epileptic patients has indicated that mTOR inhibitors may be of use in treating epilepsy associated with mutations in mTOR pathway genes. Here, we review recent advances in the molecular and genetic understanding of mTOR signaling in epileptic disorders. In particular, we focus on the development of and limitations to therapies targeting the mTOR pathway to treat epileptic seizures. We also discuss future perspectives on mTOR inhibition therapies and special diagnostic methods for intractable epilepsies caused by brain somatic mutations.
INTRODUCTION
The discovery of the mechanistic target of rapamycin (mTOR) began with the identification of new antimicrobial agents in soil samples from Rapa Nui (also known as Easter Island) 93) . This new antimicrobial agent, called rapamycin (clinically called sirolimus), was found to exhibit immunosuppressive and anti-cancer potential and to be of use as an antiepileptic drug 43, 47, 144) . For two decades, endeavors to define the function of mTOR revealed that mTOR coordinates environmental signals and metabolic activity by forming two distinct complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) 130) . mTOR was first found in brain lysates, suggesting the importance of the brain-specific function of mTOR 125) . Indeed, the mTOR pathway has been found to regulate a variety of functions in the brain from brain develop-J Korean Neurosurg Soc 62 (3) : 272-287 ment to degeneration 85) . Human genetic studies of epileptic patients and epilepsy models of aberrant activation of the mTOR pathway have demonstrated the importance of activating mutations in the mTOR pathway in neurodevelopmental disorders with epilepsy 66) . With the discovery of mutations activating the mTOR pathway as genetic causes of medically intractable epilepsy 4) , mTOR inhibitors, such as sirolimus and everolimus, have emerged as being of potential medical use in treating intractable epilepsy patients 33) . However, with the limited efficacy and significant drawbacks of clinically available mTOR inhibitors, new drugs that are more effective and tolerable based on the understanding of pathogenic mechanisms are required. Key discoveries in research on the role of the mTOR pathway in epilepsy are summarized in Supplementary Box 1.
THE MTOR PATHWAY
mTOR is a serine/threonine protein kinase that forms the core subunit of two functionally distinct protein complexes : mTORC1 and mTORC2 130) (Fig. 1 ). mTORC1 comprises three core components : mTOR, Raptor (regulatory protein associated with mTOR), and mLST8 (mammalian lethal with Sec13 protein 8, also known as GßL) 130) . In response to environmental signals, mTORC1 acts to control the balance between anabolism and catabolism 130) . mTORC2 controls proliferation, survival, and cytoskeleton organization 130) . In a nutrient-rich environment, cells convert energy sources into macromolecules, such as proteins, lipids, and nucleotides. In nutrientstarved environments, however, cells downregulate the production of macromolecules and rely on catabolic pathways, such as autophagy, for energy.
The mTOR pathway receives various inputs from upstream signaling pathways in response to growth factors, amino acids, energy, oxygen, and stress 130) , and the upstream pathways of mTOR can be divided as energy-sensing PI3K-PTEN-AKT-TSC and amino acid-sensing GATOR2-GATOR1-Rag GTPase pathways ( Fig. 2 ) : phosphatidylinositol-3-kinase (PI3K) is critical to integrating insulin signaling for growth and survival 130) . PTEN antagonizes the action of PI3K. Akt is activated by PI3K and is a positive regulator of mTORC1 via inhibition of Tuberous Sclerosis Complex (TSC). TSC is a heterotrimeric complex comprising TSC1, TSC2, and TBC1D7 38) . TSC inhibits mTORC1 by acting as a GTPase activating protein for Ras homolog enriched in brain (Rheb) 67) . Rheb is a small GTPase that activates mTORC1 by directly binding to mTORC1 on the surface of lysosomes 88) . Meanwhile, Rag GTPase, a component of the amino acid sensing pathway 127) , activates mTORC1 by promoting translocation of mTORC1 to the lysosomal surface. Upstream regulators of Rag GTPase in amino acid signaling are the GATOR1 and GATOR2 complexes 10) . The GATOR1 complex, consisting of DEPDC5, Nprl2, and Nprl3, inhibits the mTORC1 pathway by acting as a guanine exchange factor for Rag GTPase. The GATOR2 complex, consisting of Mios, WDR24, WDR59, Seh1L, and Sec13, is a positive regulator of the mTORC1 pathway by inhibiting GA-TOR1. KICSTOR, which is composed of four proteins, KPTN, ITFG2, C12orf66, and SZT2, recruits GATOR1 to the lysosome to inhibit Rag GTPase 150) . Leucyl-tRNA synthetase, which is another amino acid sensor, functions as a GTPase ac- . mTORC1 senses amino acids in an intra-lysosome fashion. Lysosomal amino acid regulates Rag GTPase via v-ATPase, which increases the guanine exchange factor activity of Ragulator towards Rag GTPase 159) . SLC38A9 is a sensor of lysosomal arginine and activates mTORC1 69) . Additional novel mTOR upstream regulators, including a methionine sensor, have recently been discovered 1, 55) . For macromolecule metabolism, mTORC1 regulates translation through inhibitory eukaryotic initiation factor 4E (eIF4E)-binding protein 1/2/3 (4E-BPs) and the S6 kinases (S6Ks) 21, 50) . Translational control occurs predominantly at the initiation step, which commences with the binding of the eukaryotic translation initiation factor 4F (eIF4F) complex to the 5'cap 52, 135) . As the limiting component of the eIF4F complex, eIF4E is considered to be a critical determinant in translation of mRNA 37) . Facilitating eIF4F formation and the progression of translation, mTORC1 phosphorylates (inactivates) the 4E-BPs, leading to their dissociation from eIF4E 51, 60) . The S6Ks activate the eukaryotic translation initiation factor 4B (eIF4B), which is an activator of the eukaryotic translation initiation factor 4A, leading to an increase in the helicase activity of eI-F4A and the initiation of translation 39, 61) . Stimulating lipid synthesis, mTORC1 interacts with the sterol responsive element binding proteins transcription factors 116) . For sufficient supply of nucleotides during growth, mTORC1 promotes purine and pyrimidine nucleotide biosynthesis through MTHFD2 and the carbamoyl-phosphate synthetase 17) . Through increased translation of the HIF1α transcription factor that drives the expression of glycolytic enzymes, mTORC1 further promotes growth by changing glucose metabolism from oxidative phosphorylation to glycolysis 130) . The mTORC1 pathway also activates the transcriptional coactivator PGC1α for increased mitochondrial biosynthesis 34) . Meanwhile, mTORC1 inhibits autophagy, which plays an important role in scavenging damaged and harmful cellular structures and sustains energy homeostasis, through ULK1 118) . Recently, it was also demonstrated that mTORC1 regulates ribosomal protein degradation through NUFIP1 151) . mTORC2 largely functions as a primary effector of the insulin/PI3K signaling 130) (Fig. 2) . Generally, the role of the mTORC2 pathway is thought to overlap with the insulin signaling pathway, considering that phenotypes caused by perturbation of the mTORC2 pathway are very similar to those elicited by perturbation of insulin signaling 105) . Upon phosphorylation by mTORC2 128) , Akt promotes cell survival and proliferation. mTORC2 further regulates cellular proliferation and survival through the AGC (PKA/PKG/PKC) family of protein kinases.
PHYSIOLOGICAL ROLES OF THE MTOR PATH-WAY IN THE BRAIN
The mTOR pathway plays important roles in development and aging of the central nervous system (CNS) : the mTORC1 pathway is a core regulator of neural development, cortical architecture, neuronal morphology, circuit formation, synaptic plasticity, and neurodegeneration 85) . Perturbation of the mTOR pathway has been found to disrupt several developmental processes. Defective telencephalic development was reported in mTOR mutant rats, called "flat-top" mutants 59) . The loss of function of tuberous sclerosis complex 2 (Tsc2), which is an upstream inhibitor of mTOR, was found to disrupt neuroepithelial growth 119) . Altogether, these studies demonstrated that the mTOR pathway is important for brain development by regulating neural stem cells. Meanwhile, activation of the mTOR pathway via conditional deletion of Tsc2 was found to lead to the disruption of cortical layering 147) . Additionally, increased activity of the mTOR pathway due to mTOR mutations, loss of Tsc1/2, or Pten, was described as eliciting hypertrophy of soma, fewer dendritic spine, increased axon length, and increased dendritic complexity in cortical neurons 53, 77, 78, 137, 138) . Perturbation of the mTOR pathway has also been found to adversely affect neural circuit formation. The mTOR pathway regulates axon length 53) and axon guidance in response to environmental signals 156) . Among neurons, local protein synthesis in synapses distant from the soma is mediated by mTOR and is critical for the formation of the neural circuit. The expression levels of synaptic proteins, such as the Arc and Synapsin, are increased by activation of mTOR 81, 117) . Hyperactivation of the mTOR pathway by loss of Pten has been shown to increase glutamatergic and GABAergic signals 148) . In addition to neurons, the mTOR pathway has been found to regulate glial cells during neural circuit formation. Deletion of the core component of the mTORC1 or the mTORC2, Raptor or Rictor, was reported to result in defective myelination and oligodendrocyte maturation 18, 146) . Conditional Tsc1 knockout in the astrocyte reportedly disrupted electrical signaling in the mouse brain by abrogating neural circuitry 141) . Interestingly, researchers have discovered crosstalk between neurons and glial cells as evidenced by a loss of myelination upon loss of TSC1 in neurons 96) . In TSC patients, the critical role of the mTOR pathway in neural circuit formation was echoed by reductions in white matter and cortical connectivity 112) . Neuronal synapses are crucial to storing memories. Observations of impaired memory formation and synaptic function in response to rapamycin treatment suggest the important role of the mTOR pathway in memory formation 25) . Indeed, the mTOR pathway has been found to play a crucial role in both long-term potentiation (LTP) and long-term depression (LTD) : activation of the mTOR pathway via Tsc1+/-, Tsc2+/-, or 4E-BP2 knockout (KO), results in a decrease in LTP threshold 8, 41, 145) . Meanwhile, reduced mTOR pathway activity disrupts LTD through metabotropic glutamate receptors (mGluRs) that disturb local protein synthesis 62, 64) .
ACTIVATION OF MTOR PATHWAY IN NEURODE-VELOPMENTAL DISORDERS WITH EPILEPSY
Neurodevelopmental disorders, such as malformations of cortical development (MCD), Cowden syndrome (CS), PIK-3CA-related overgrowth spectrum (PROS), and hamartoma tumor syndromes, commonly present cortical abnormalities and are highly associated with epilepsy, developmental delay, and autism-spectrum disorders 4, 12, 70, 80, 97, 106, 133) . These neurodevelopmental disorders with epilepsy are a common cause of drug-resistant epilepsy in children requiring surgery for treatment 4, 12) . However, about 50% of these individuals continue to experience seizures after surgical resection of the epileptic focus 94) . In addition to clinical intractability, refractory epileptic seizures also pose tremendous socioeconomic burden, based https://doi.org/10.3340/jkns.2019.0027 on poor quality of life, to patients and their caregivers 28) . Aberrant activation of the mTOR pathway has been identified in brain lesions from patients with neurodevelopmental disorders with epilepsy, especially in MCD 15, 86, 100) . With these results, researchers have suspected genetic mutations as culprits of the observed mTOR pathway activation in neurodevelopmental disorders 32) . Indeed, a number of neurodevelopmental disorders with epilepsy has been shown to be caused by germline or somatic mutations in the mTOR pathway : these mutations can be categorized as those affecting the energy-sensing PI3K-PTEN-AKT-TSC pathway and those affecting the amino acid-sensing GATOR2-GATOR1-Rag GTPase pathway (Table 1) .
MUTATIONS IN THE ENERGY-SENSING PI3K-PTEN-AKT-TSC PATHWAY
Germline mutations in the PIK3CA gene, which activates the mTOR pathway, have been reported in CS 106) . Character- ized by hamartomatous overgrowth of tissues, CS is also accompanied by epileptic seizure in a subset of patients 98, 113) . There are also other brain and body overgrowth disorders with epilepsy that are caused by post-zygotic mutations in the PIK3CA pathway, which are termed PROS 70) . Additionally, mosaic or brain somatic mutations in PIK3CA have been reported in several other neurodevelopmental disorders with epilepsy, including the megalencephaly (MEG), hemimegalencephaly (HME), megalencephaly-capillary malformation (MCAP), megalencephaly-polydactyly-polymicrogyria-hydrocephalus syndromes, and focal cortical dysplasia (FCD) type IIa/IIb 36, 68, 79, 99, 122, 132) . Classically, germline PTEN mutation has been reported in hamartoma tumor syndromes, including CS, Bannayan-Riley-Ruvalcaba syndrome, Lhermitte-Duclos disease, Proteus syndrome, and Proteus-like conditions that share the pathological phenotypes of macrocephaly and megalencephaly 97) . Epileptic seizures have been reported in patients with germline mutation in PTEN 29, 30, 90) . Brain somatic mutations in AKT3 have primarily been detected in MCD, including the HME and FCD. Brain somatic gain of function mutations in AKT3 were first demonstrated to cause HME 79) , followed by identification of somatic AKT3 mutations in FCD 68) . Germline AKT3 mutations were also reported in MEG 104) . To date, germline AKT3 mutations have been reported in HME, MEG, MEG with polymicrogyria, and MEG with periventricular nodular heterotopia 2) . TSC1 and TSC2 germline mutations have been identified in TSC patients 142) . Brain somatic mutations in TSC1 and TSC2 have also been discovered in FCD type IIb 82) . Homozygous TBC1D7 loss of function mutation have been identified in MEG patients 3, 22) . More recently, brain somatic mutation in RHEB were identified in an HME patient 126) . STE20-related kinase adaptor α (STRADA) is a negative regulator of mTOR, by activating AMPK 107) . A loss-of-function mutation in STRADA was reported in autosomal recessive disease polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome, also called Pretzel syndrome (PMSE) 111) . Germline or mosaic mutation in MTOR has been described in the Smith-Kingsmore syndrome (SKS) OMIM #616638, which is characterized by epileptic seizure and neurodevelopmental defect 54) . SKS is a rare disease for which only 23 patients have been reported as of 2018 54, 101, 102) . Brain somatic mutations in MTOR have also been described in FCD and HME, with varying degrees of mutational burden 91) . All of these mutations have been found to be missense gain-of-function mutations that activate the mTOR pathway.
MUTATIONS IN THE AMINO ACID-SENSING

GATOR2-GATOR1-RAG GTPASE PATHWAY
Amino acid-sensing pathway is mediated by the GATOR2-GATOR1-Rag GTPase pathway. Since GATOR1 is a negative regulator of the mTORC1 pathway, researchers proposed that loss-of-function of GATOR1 would lead to neurodevelopmental disorders with epilepsy via hyperactivation of the mTORC1 pathway. Germline mutations in DEPDC5, NPRL2, and NPRL3 have been reported in familial focal epilepsy with variable foci, autosomal dominant nocturnal epilepsy, temporal lobe epilepsy, and familial mesial temporal lobe epilepsy 13, 121) . In addition, germline mutations in DEPDC5, NPRL2, and NPRL3 have also been discovered in MCD and epileptic spasms patients 24, 131, 134) . Additionally, mosaicism and brain somatic mutation in GATOR1 have been reported in MCD 36) , pachygyria 26) and familial focal epilepsy with focal cortical dysplasia 14) . Interestingly, it was recently demonstrated that epilepsy patients with focal cortical dysplasia carry a germline mutation in one allele of DEPDC5 and a brain somatic mutation in the other allele, suggesting a two-hit hypothesis as a disease mechanism 14, 120) . Autosomal recessive mutations in the KICSTOR complex, including KPTN 9, 108) , SZT2 11, 143) , and the genomic locus that contains C12orf66 95) , have been identified in neurodevelopmental disorders with epilepsy. Until now, mutations in GATOR2 have not been identified in epilepsy patients.
EPILEPSY ANIMAL MODELS OF HYPERACTIVA-TION OF THE MTOR PATHWAY
For extensive research into epilepsy, genetic animal models of mutations activating the mTOR pathway in epilepsy patients have been developed (Table 2) . The first genetic model of epilepsy was the Pten KO mouse reported in 2001 6, 78) . Although Eker rats with germline mutations in the Tsc2 gene were the first genetic animal model of mTOR hyperactivation, the model was not suitable for analyzing epileptic seizures due https://doi.org/10.3340/jkns.2019.0027 to early phase lethality 155) . In 2002, the first TSC model with epilepsy, which was the astrocyte-specific Tsc1 KO model, was reported 141) ; neuron-specific KO of Tsc1 was also found to lead to spontaneous seizure in the mouse model 96) . After these, the Tsc2 GFAP KO mouse model was developed and shown to lead to epilepsy 157) . A mouse model expressing human PI3KCA mutation in developing neural progenitors was generated to recapitulate pathological features of PROS syndrome, including epilepsy 123) . A knock-in mouse model with gain-of-function mutation in Akt3 has also been found to elicit spontaneous seizure 140) .
Recently, epilepsy models of brain somatic mutations, which recapitulate focal malformations of cortical development (FMCD), have been reported. A mouse model of FMCD was first generated by in utero electroporation, thereby providing a small portion of neurons to express known mTOR mutations in human FMCD patients 7, 83, 110) ; these models developed spontaneous seizures. Additionally, FMCD models of brain somatic mutation in mTOR pathway genes, such as RHEB or TSC, have consistently recapitulated spontaneous seizures 63, 82) . Heterozygote GATOR1 gene (Depdc5, Nprl2, and Nprl3) KO animals have not been found to recapitulate epileptic seizures observed in patients with germline mutations in the GATOR1 genes 40, 65, 72, 92) . Interestingly, FMCD mouse model caused by a biallelic two-hit mutation (brain somatic and germline) in Depdc5 was shown to lead to spontaneous seizure 120) . Homozygous KO of Szt2, a component of the KIC-STOR complex, has been reported as leading to low seizure threshold in mice 46) . 
MTOR PATHWAY ACTIVATION IN EPILEPTO-GENESIS
Epileptogenesis refers to the process leading to the first spontaneous seizure after pro-epileptogenic insult (e.g., genetic defect, brain injury, status epilepticus, or cancer). Epileptogenesis is a brain-wide circuit rewiring process comprising reorganization of microcircuits to long-range circuits, as well as gliosis, blood-brain barrier damage, inflammation, and neurodegeneration 114) . Since epilepsy is the consequence of electrical changes, electrophysiological characteristics in animal models and epilepsy patients have been analyzed in an attempt to understand the epileptogenic mechanism. Studies have indicated that highfrequency oscillations on electroencephalogram are characteristic of FCD 20) . Organotypic brain slice analysis of resected FCD lesions has revealed an electrographic firing pattern of ictal-like discharges after 4-aminopyridine treatment 5) , which decreased with treatment with GABA A receptor antagonist.
In brain slice cultures of hyperactive mTOR signaling, researchers have found both the frequency and amplitude of the miniature excitatory postsynaptic current to be increased in glutamatergic synaptic transmission of the hippocampus 89, 138) . In GABAergic neurons, hyperactive mTOR signaling increased evoked synaptic responses in the hippocampus 148) . In a subset of auditory cortical neurons of Pten conditional KO, synaptic inputs from the long-range connections, including the contralateral auditory cortex and thalamus, and local connections were increased 152) .
In an epilepsy animal model of brain somatic mutations in the mTOR pathway, mutation-carrying cortical neurons showed an increased capacitance, increased cell size, reduced input resistance indicative of a higher current needed to reach the voltage threshold of the action potential, and increased gain of firing frequency 120) . Also, spontaneous excitatory postsynaptic current frequency was decreased in the mTOR pathway mutation-carrying cortical neurons 84, 120) . There have been tremendous advances in the identification of the contribution of mTOR downstream functions to neuronal hypertrophy, dendritic branching, axon length, and neuronal migration. Although numerous epilepsy animal models have been utilized to unravel the path to epileptogenesis, the downstream mechanism of mTOR signaling that accounts for epileptogenesis remains unclear. The complexity of the downstream output of the mTOR pathway has hampered attempts to understand the epileptogenic mechanism. Using genetic manipulation techniques, normalizing major downstream outputs of hyperactive mTOR signaling, including translation via overexpressing constitutively active 4E-BP or knockdown of S6Ks 84) and autophagy via knockdown of OFD1 110) , have failed to prevent or even reduce epileptogenesis. Further studies defining the downstream pathway of mTOR in epileptogenesis will be necessary.
INHIBITION OF THE MTOR PATHWAY IN TREAT-MENT OF EPILEPTIC DISORDERS
Researchers have hypothesized that epilepsy resulting from mTOR pathway activation could be treated by mTOR inhibition, and mTOR inhibition therapies have been evaluated in several clinical trials for epilepsy (Table 3) . Rapalogs, including sirolimus and everolimus, have been reported as promising new anti-epileptics because they can penetrate the blood brain-barrier 71) . Rapalogs have been extensively tested and have gained the US Food and Drug Administration (FDA) approval as anti-epileptics in TSC 27, 47, 73) . The first study to show the beneficial effect of the rapalogs on epilepsy did so in a mouse model of TSC 158) . In this study, early treatment with sirolimus prevented the development of epilepsy. The anti-epileptic effect of rapalogs has also been demonstrated in other genetic models of epilepsy with mTOR pathway hyperactivation, including Pten 87) KO and Strada
KO 111)
. Recently, intractable epilepsy mouse models with brain somatic mutation in the mTOR pathway were found to be cured by rapalogs 63, 82, 83) . Interestingly, epileptic seizure was almost completely suppressed by mTOR inhibitors in mouse models of TSC KO or mTOR activating mutation, but only partially suppressed in Pten KO mouse models 87) . These results suggest that an independent mechanism of epileptogenesis distinct from that in TSC KO or mTOR mutation is present in the Pten KO model. In nongenetic seizure models, including the pilocarpine-induced epilepsy model, kainic acid-induced epilepsy model, and absence epilepsy model, rapalogs partially reduced seizures. Citraro et al. subependymal giant astrocytoma, kidney tumors, and partial epilepsy in TSC patients. The first trial to test the efficacy of everolimus to treat epileptic seizure was reported in 2010 for TSC patients 74) . In this study, seizure frequency was reduced in nine of 16 patients with everolimus. Following studies supported the anti-epileptic effects of everolimus or sirolimus ( Table 3) .
The prospective, randomized, multicenter, placebo-controlled study testing the seizure suppression effect of everolimus on seizure frequency in TSC patients with drug-resistant epilepsy reported positive results 49) . Recently, long-term results of the prospective, open-label, non-randomized study of everolimus for treating epileptic seizure in TSC indicated that reduction in seizure frequency is sustained for up to 4 years 75) . This effect has been confirmed in the long-term follow-up of the EXIST3 trial 35) . Large-scale studies on the anti-epileptic effect of everolimus have described response rates for everolimus and a median seizure frequency reduction in respondents of about 40% 35, 75) . In 2017 and 2018, respectively, both the European Medicinal Agency in Europe and the US FDA approved everolimus as an adjunctive therapy in partial-onset seizures in TSC patients aged 2 years and older. However, there are reports of non-responders, seizure aggravation, or an withdrawal after everolimus administration 35, 149) . Meanwhile, clinical trials for treating epileptic seizure in FCD type II with everolimus have recently started (clinicaltrials.gov identifier NCT03198949).
The first report of the anti-epileptic effect of sirolimus in TSC patients, which appears to be similar to that of everolimus 23) , was in 2009 103) . In HME patients with brain somatic mutation in mTOR, sirolimus administration reduced seizures 153) . Interestingly, sirolimus has been shown to prevent epilepsy in PMSE patients 111) . Animal and human treatment studies reported that withdrawal of rapalogs provokes seizure recurrence 73) . In electrophysiological analysis of brain slices of resected epileptic foci, everolimus was found to reduce spontaneous excitatory postsynaptic activity, burst discharges, and epileptiform activity in TSC, FCD, and HME cases; effects were subtle in epilepsy patients without mTOR mutations 27) . While rapalogs have been approved for use in various human diseases, concerns have been raised for their long-term use and their adverse effect profile, including potentially serious adverse effects. The adverse effects of rapalogs include im- Seizure reduction (over 50%) 31) mTOR : mechanistic target of rapamycin, TSC : tuberous sclerosis, PMSE : polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome, HME : hemimegalencephaly https://doi.org/10.3340/jkns.2019.0027 munosuppression, mucositis, hyperlipidemia, hyperglycemia, diabetes-like syndrome, and fatal pneumonitis 42, 76, 109, 139) . In a phase III clinical trial with everolimus, over 90% of 111 patients experienced an adverse effects of any grade 48) . With everolimus treatment for over 1 year, grade 3 or 4 adverse events, which are severe adverse events, were reported in 45% of younger patients and 38% of older patients among 150 patients 35) . We should stress that developmental delay caused by rapalogs 63) should be a concern, considering that the onset of intractable epilepsy with mTOR pathway mutation is usually before adolescence 4) . Additionally, treatment with rapalogs has been found to induce adverse nervous system-specific effects altering sociability 129) , learning and memory 16, 25) , and anxiety 56) in mouse models.
For epilepsy caused by brain somatic mutations, therapeutic regimens must seek to avoid perturbations outside of the CNS, and in this regard, antisense oligonucleotide (ASO) drugs appear to be promising therapeutic options. ASO is a complementary oligonucleotide sequence of sense mRNA sequences that hampers normal gene expression processes, including splicing, transcription, and translation 136) . The characteristics of the bloodbrain barrier prevent ASO from permeating outside of the CNS when administered into the cerebrospinal fluid via intrathecal injection. Moreover, the half-life of ASO drugs is more than 3 months 19) . Recently, ASO drugs have been approved by the FDA for treating various types of neurodegenerative disorders 45) . We suspect that intrathecal injection of ASO drugs targeting mTOR itself, mTOR mutation, or downstream targets of mTOR will prove effective in treating intractable epilepsies while avoiding the adverse effects of rapalogs outside of the CNS.
CONCLUSION
Over the last two decades, extensive research to outline the roles of the mTOR pathway, to identify mutations in the mTOR pathway in human epilepsy patients, and to develop mTOR inhibitors have led to the discovery of novel strategies for diagnosing and treating intractable epilepsy. The overarching goal of this clinical research is attaining seizure-free status with few to no adverse effects in epilepsy patients. While rapalogs have proven to be effective in controlling seizures, complete seizure cessation has not been recorded in most of patients 35, 75) . Also, about half of all TSC patients fail to respond to rapalogs. These discrepancies suggest that there might be an unknown biological mechanism at play. Considering about 40% of patients treated with rapalogs experience a severe adverse effect, it will be necessary to develop more potent and tolerable therapies.
While FMCD patients with drug-resistant epilepsy typically undergo surgical resection of the epileptic focus for treating the seizure, up to 50% of patients do not respond to therapy. Based on preclinical and clinical studies of TSC with rapalogs, it may no longer be necessary to perform highly invasive surgical resection for seizure treatment. However, there is a problem in that diagnosing FMCD patients with low-frequency brain somatic mutation in the mTOR pathway requires analyzing DNA from brain tissue after surgical resection. To alleviate this issue, minimally invasive diagnosis through biomarkers in patient cerebrospinal fluid would prove invaluable.
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